Evotec Signs High Throughput Screening Collaboration with Alios Biopharma, Inc

22-Jul-2009 - Germany

Evotec AG announced a collaboration with Alios Biopharma, Inc in the area of high throughput screening (HTS).

Alios BioPharma, Inc. is a biotechnology company that is developing novel medicines that treat diseases in virology by activating pathways in the innate immune system.

Evotec will use its proprietary ultra-HTS platform and technology to screen a priority biological target for Alios. Evotec's HTS technology has been developed in collaboration with its pharmaceutical partners Pfizer, Novartis and GSK. It combines an ultra sensitive detection technology with a miniaturized screening format providing a throughput unrivalled within the industry. In addition, Alios will access Evotec's small molecule screening library for the screen.

Dr Leonid Beigelman, Executive Vice President of Research, from Alios commented: "Evotec has compiled a small molecule screening library that provides excellent diversity and high quality. This, combined with their exceptional HTS technology makes them an ideal partner for screening our important target with the aim of finding high quality hits for our subsequent medicinal chemistry efforts."

No financial details are disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances